Table 4.
Ref. | n |
Prognostic factors for positive NSLNs |
|||||||||||
Tumor grade | Size of positive SLN | Proportion of positive SLN | Molecular subtype | Tumor size | Age | Nb of SLN examined | Presence of LVI | Histologic type | Multicentric tumor | ECE | Tumor location | ||
Zhou et al[26] | 130 (pN1mi 25%) | + | + | + | + | + | - | - | NR | NE | NE | NE | NE |
Meretoja et al[16] | 1000 (pN1mi 28%) | - | + | + | + | + | NR | NR | + | - | + | + | NE |
Houvenaeghel et al[17] | 909 (pN1mi 100%) | - | + | NR | NR | + | NR | NR | + | + | NE | NE | NE |
Tvedskov et al[20] | 1881 (pN1mi 100%) | - | NR | + | + | + | - | - | + | - | - | - | + |
NSLN: Non-sentinel lymph node; SLN: Sentinel lymph node; LVI: Lymphovascular invasion; ECE: Evaluable capsular effraction; NR: Not reported; NE: Non evaluable.